Brokers Offer Predictions for PHIO Q1 Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Equities research analysts at Sidoti Csr issued their Q1 2027 earnings estimates for Phio Pharmaceuticals in a research report issued on Monday, November 17th. Sidoti Csr analyst A. Hantman anticipates that the company will post earnings per share of ($0.18) for the quarter. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share. Sidoti Csr also issued estimates for Phio Pharmaceuticals’ Q2 2027 earnings at ($0.19) EPS and Q3 2027 earnings at ($0.20) EPS.

Several other equities research analysts have also recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright restated a “buy” rating and issued a $14.00 price objective on shares of Phio Pharmaceuticals in a report on Friday, August 15th. Finally, Wall Street Zen cut shares of Phio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $14.00.

Phio Pharmaceuticals Stock Performance

PHIO stock opened at $1.27 on Wednesday. Phio Pharmaceuticals has a one year low of $0.97 and a one year high of $9.79. The firm has a market cap of $7.27 million, a PE ratio of -0.39 and a beta of 0.97. The firm’s 50 day moving average price is $2.05 and its 200-day moving average price is $2.15.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its earnings results on Thursday, November 13th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01.

Institutional Investors Weigh In On Phio Pharmaceuticals

An institutional investor recently raised its position in Phio Pharmaceuticals stock. Geode Capital Management LLC increased its position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) by 38.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,694 shares of the company’s stock after buying an additional 16,108 shares during the period. Geode Capital Management LLC owned about 1.20% of Phio Pharmaceuticals worth $136,000 at the end of the most recent reporting period. Institutional investors own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.